Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

In vitro studies with melphalan and pediatric neoplastic and normal bone marrow cells.

Worthington-White DA, Graham-Pole JR, Stout SA, Riley CM.

Int J Cancer. 1986 Jun 15;37(6):819-23.

PMID:
3458679
2.

High-dose melphalan therapy for the treatment of children with refractory neuroblastoma and Ewing's sarcoma.

Graham-Pole J, Lazarus HM, Herzig RH, Gross S, Coccia P, Weiner R, Strandjord S.

Am J Pediatr Hematol Oncol. 1984 Spring;6(1):17-26.

PMID:
6370012
3.

High dose melphalan in children with advanced malignant disease. A pharmacokinetic study.

Ninane J, Baurain R, de Selys A, Trouet A, Cornu G.

Cancer Chemother Pharmacol. 1985;15(3):263-7.

PMID:
4053270
4.

High-dose intravenous melphalan: a review.

Samuels BL, Bitran JD.

J Clin Oncol. 1995 Jul;13(7):1786-99. Review.

PMID:
7602368
5.

Pharmacokinetics of melphalan in children following high-dose intravenous injection.

Taha IA, Ahmad RA, Rogers DW, Pritchard J, Rogers HJ.

Cancer Chemother Pharmacol. 1983;10(3):212-6.

PMID:
6861266
6.
8.

Preclinical evidence that use of TRAIL in Ewing's sarcoma and osteosarcoma therapy inhibits tumor growth, prevents osteolysis, and increases animal survival.

Picarda G, Lamoureux F, Geffroy L, Delepine P, Montier T, Laud K, Tirode F, Delattre O, Heymann D, Rédini F.

Clin Cancer Res. 2010 Apr 15;16(8):2363-74. doi: 10.1158/1078-0432.CCR-09-1779. Epub 2010 Apr 6.

9.

Preclinical efficacy of the bioreductive alkylating agent RH1 against paediatric tumours.

Hussein D, Holt SV, Brookes KE, Klymenko T, Adamski JK, Hogg A, Estlin EJ, Ward T, Dive C, Makin GW.

Br J Cancer. 2009 Jul 7;101(1):55-63. doi: 10.1038/sj.bjc.6605100. Epub 2009 Jun 2.

10.

Busulfan-Melphalan followed by autologous stem cell transplantation in patients with high-risk neuroblastoma or Ewing sarcoma: an exposed-unexposed study evaluating the clinical impact of the order of drug administration.

Dourthe ME, Ternès N, Gajda D, Paci A, Dufour C, Benhamou E, Valteau-Couanet D.

Bone Marrow Transplant. 2016 Sep;51(9):1265-7. doi: 10.1038/bmt.2016.109. Epub 2016 Apr 25. No abstract available.

PMID:
27111042
11.

Consolidation of first-line therapy with busulphan and melphalan, and autologous stem cell rescue in children with Ewing's sarcoma.

Drabko K, Raciborska A, Bilska K, Styczynski J, Ussowicz M, Choma M, Wojcik B, Zaucha-Prazmo A, Gorczynska E, Skoczen S, Wozniak W, Chybicka A, Wysocki M, Gozdzik J, Kowalczyk J.

Bone Marrow Transplant. 2012 Dec;47(12):1530-4. doi: 10.1038/bmt.2012.78. Epub 2012 May 21.

PMID:
22609883
12.

Hemopoietic reconstitution after repeated autologous transplantation with mafosfamide-purged marrow.

Beaujean F, Hartmann O, Benhamou E, Lemerle J, Duedari N.

Bone Marrow Transplant. 1989 Sep;4(5):537-41.

PMID:
2790332
13.

Evaluation of chemotherapy in children with metastatic Ewing's sarcoma and osteogenic sarcoma.

Sutow WW, Vietti TJ, Fernbach DJ, Lane DM, Donaldson MH, Lonsdale D.

Cancer Chemother Rep. 1971 Feb;55(1):67-78. No abstract available.

PMID:
5287340
14.

High-dose sequential chemotherapy and autologous stem cell reinfusion in advanced pediatric solid tumors.

Chan KW, Petropoulos D, Choroszy M, Herzog C, Jaffe N, Ater J, Korbling M.

Bone Marrow Transplant. 1997 Dec;20(12):1039-43.

15.

High dose melphalan with autologous marrow rescue in cancer treatment.

Dewar JM, Forgeson GV, Dady PJ.

N Z Med J. 1984 Nov 28;97(768):816-8.

PMID:
6390271
16.

Cytotoxicity of treosulfan and busulfan on pediatric tumor cell lines.

Lanvers-Kaminsky C, Bremer A, Dirksen U, Jürgens H, Boos J.

Anticancer Drugs. 2006 Jul;17(6):657-62.

PMID:
16917211
17.

High dose melphalan with autologous bone marrow transplantation in the treatment of metastatic Ewing's sarcoma.

McCann SR, Reynolds M, Meldrum R, Breslin B, Walsh T, Temperley IJ, Daly PA.

Ir J Med Sci. 1983 Apr;152(4):160-4. No abstract available.

PMID:
6347959
18.
19.

Supplemental Content

Support Center